JP2024524158A - タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 - Google Patents

タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 Download PDF

Info

Publication number
JP2024524158A
JP2024524158A JP2023578067A JP2023578067A JP2024524158A JP 2024524158 A JP2024524158 A JP 2024524158A JP 2023578067 A JP2023578067 A JP 2023578067A JP 2023578067 A JP2023578067 A JP 2023578067A JP 2024524158 A JP2024524158 A JP 2024524158A
Authority
JP
Japan
Prior art keywords
tasquinimod
amount
sample
compound
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524158A5 (https=
Inventor
ウェンマン，ハンス
Original Assignee
アクティブ バイオテック エイビー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクティブ バイオテック エイビー filed Critical アクティブ バイオテック エイビー
Publication of JP2024524158A publication Critical patent/JP2024524158A/ja
Publication of JP2024524158A5 publication Critical patent/JP2024524158A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023578067A 2021-07-02 2022-06-30 タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 Pending JP2024524158A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21183481.7 2021-07-02
EP21183481 2021-07-02
PCT/EP2022/068063 WO2023275248A1 (en) 2021-07-02 2022-06-30 A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Publications (2)

Publication Number Publication Date
JP2024524158A true JP2024524158A (ja) 2024-07-05
JP2024524158A5 JP2024524158A5 (https=) 2025-05-26

Family

ID=76764937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578067A Pending JP2024524158A (ja) 2021-07-02 2022-06-30 タスキニモドを含有する医薬製品および前記製品の純度を評価する方法

Country Status (10)

Country Link
US (1) US20240277693A1 (https=)
EP (1) EP4363404A1 (https=)
JP (1) JP2024524158A (https=)
KR (1) KR20240029029A (https=)
CN (1) CN117500790A (https=)
AU (1) AU2022303084A1 (https=)
CA (1) CA3221689A1 (https=)
IL (1) IL309486A (https=)
MX (1) MX2023014668A (https=)
WO (1) WO2023275248A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024306742A1 (en) * 2023-06-28 2025-12-04 Active Biotech Ab Quinoline carboxamides for use in the treatment of mpn
WO2025228998A1 (en) * 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
SG186430A1 (en) 2010-07-09 2013-01-30 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CN105367492B (zh) * 2014-08-28 2018-07-03 杭州普晒医药科技有限公司 他喹莫德的晶型及其制备方法、其药物组合物和用途
JP6647287B2 (ja) 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
MX379401B (es) 2014-11-19 2025-03-11 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
BR112023000892A2 (pt) 2020-07-23 2023-02-07 Univ Erasmus Med Ct Rotterdam Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor

Also Published As

Publication number Publication date
MX2023014668A (es) 2024-01-12
EP4363404A1 (en) 2024-05-08
KR20240029029A (ko) 2024-03-05
WO2023275248A1 (en) 2023-01-05
AU2022303084A1 (en) 2024-01-25
US20240277693A1 (en) 2024-08-22
CA3221689A1 (en) 2023-01-05
CN117500790A (zh) 2024-02-02
IL309486A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
JP2022507495A (ja) 癌治療のための医薬の組合せ
US20240307398A1 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
TW202136225A (zh) 製備４－（２－氯－４－甲氧基－５－甲基苯基）－ｎ－［（１ｓ）－２－環丙基－１－（３－氟－４－甲基苯基）乙基］－５－甲基－ｎ－丙－２－炔基－１，３－噻唑－２－胺之合成方法
JP7445597B2 (ja) キノロン類似体及びそれらの塩、組成物、ならびにそれらの使用方法
JP2022506062A (ja) 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用
CN102351857A (zh) 盐酸托烷司琼化合物
JP2024524158A (ja) タスキニモドを含有する医薬製品および前記製品の純度を評価する方法
JP6215238B2 (ja) Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
JP2021532193A (ja) 生物学的に利用可能な経口剤形
TW201427668A (zh) 治療和布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶相關之疾病或失調的方法
PT2288341T (pt) Utilização de uma matriz para administração oral de magnésio de libertação prolongada e composição contendo esta matriz
BR112016016021B1 (pt) Composição farmacêutica, seu uso, formulação de dosagem oral e método para preparar comprimido por compressão direta em formulação de dosagem única
US20260076908A1 (en) Plurality of tasquinimod particles and use thereof
JPWO2018230504A1 (ja) 顆粒剤、並びに錠剤及びその製造方法
CN101671338A (zh) 枸橼酸爱地那非晶型d及其制备方法和用途
JP2021523195A (ja) Ｈｃ−１１１９製剤及びその製造方法と使用
US20250120981A1 (en) Mrtx1133 pharmaceutical compositions
JP2025038130A (ja) エストロゲン受容体アルファ阻害剤の経口剤形を用いて癌を治療する方法
CN105646520A (zh) 一种稳定的艾日布林化合物
Trivedi et al. Nintedanib as the First Treatment for Group of Progressive Interstitial Lung Diseases: A Review of Patent Literature
CN101619039B (zh) 2-(4-乙基-1-哌嗪基)-4-(4-氟苯基)-5,6,7,8,9,10-六氢芳辛并[b]吡啶及其组合物
CN106478598B (zh) 一种凡德他尼水合物晶体及其制备方法
JP2022500441A (ja) 結晶性（ｒ）−５−カルバモイルピリジン−３−イル−２−メチル−４−（３−（トリフルオロメトキシ）ベンジル）ピペラジン−１−カルボキシレート、組成物、及びその使用方法
JP7287955B2 (ja) シス－４－［２－｛［（３ｓ，４ｒ）－３－フルオロオキサン－４－イル］アミノ｝－８－（２，４，６－トリクロロアニリノ）－９ｈ－プリン－９－イル］－１－メチルシクロヘキサン－１－カルボキサミドの組成物及び使用方法
HK40107035A (en) A plurality of tasquinimod particles and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250509